Gaucher disease type I and pregnancy

1989 ◽  
Vol 32 (4) ◽  
pp. 475-477 ◽  
Author(s):  
J. Zlotogora ◽  
M. Sagi ◽  
M. Zeigler ◽  
G. Bach
Keyword(s):  
2019 ◽  
Vol 22 (06) ◽  
pp. 103-117
Author(s):  
Mays Al-Tai ◽  
Deia Al-Asady ◽  
Rula Hamid

1981 ◽  
Vol 9 (2) ◽  
pp. 333P-333P
Author(s):  
A. Chabás ◽  
C. Costa ◽  
J. Sabater
Keyword(s):  

2015 ◽  
Vol 34 (2) ◽  
pp. 328 ◽  
Author(s):  
Mehmet Agilli ◽  
Fevzi Nuri Aydin ◽  
Yasemin Gulcan Kurt

2015 ◽  
Vol 34 (4) ◽  
pp. 727-731 ◽  
Author(s):  
Divair Doneda ◽  
André L. Lopes ◽  
Bruno C. Teixeira ◽  
Suzana D. Mittelstadt ◽  
Cileide C. Moulin ◽  
...  

2013 ◽  
Vol 10 (1) ◽  
pp. 34 ◽  
Author(s):  
Divair Doneda ◽  
Cristina B Netto ◽  
Cileide C Moulin ◽  
Ida Vanessa D Schwartz

2000 ◽  
Vol 23 (4) ◽  
pp. 387-390 ◽  
Author(s):  
R. Barone ◽  
G. Giuffrida ◽  
R. Musso ◽  
G. Carpinteri ◽  
A. Fiumara

Blood ◽  
2007 ◽  
Vol 110 (7) ◽  
pp. 2296-2301 ◽  
Author(s):  
Deborah Elstein ◽  
Altoon Dweck ◽  
Drorit Attias ◽  
Irith Hadas-Halpern ◽  
Shoshana Zevin ◽  
...  

Enzyme replacement therapy (ERT) with imiglucerase reduces hepatosplenomegaly and improves hematologic parameters in Gaucher disease type 1 within 6-24 months. Miglustat reduces organomegaly, improves hematologic parameters, and reverses bone marrow infiltration. This trial evaluates miglustat in patients clinically stable on ERT. Tolerability of miglustat and imiglucerase, alone and in combination, pharmacokinetic profile, organ reduction, and chitotriosidase activity were assessed. Thirty-six patients stable on imiglucerase were randomized into this phase II, open-label trial. Statistically significant changes from baseline were assessed (paired t test) on primary objectives with secondary analyses on biochemical and safety parameters. Liver and spleen volume were unchanged in switched patients. No significant differences were seen between groups regarding mean change in hemoglobin. Mean change in platelet counts was only significant between miglustat and imiglucerase groups (P = .035). Chitotriosidase activity remained stable. In trial extension, clinical endpoints were generally maintained. Miglustat was well tolerated alone or in combination. Miglustat's safety profile was consistent with previous trials; moreover, no new cases of peripheral neuropathy were observed. Gaucher disease type 1 (GD1) parameters were stable in most switched patients. Combination therapy did not show benefit. Findings suggest miglustat could be an effective maintenance therapy in stabilized patients with GD1.


2021 ◽  
Vol 11 (2) ◽  
pp. 46-67
Author(s):  
A.A. Medenikov ◽  
◽  
E.D. Vyshedkevich ◽  
R.E. Shtentsel’ ◽  
A.YU. Efimtsev ◽  
...  

2020 ◽  
Vol 47 (3) ◽  
pp. 22-25
Author(s):  
D. Nikolova ◽  
A. Yordanov ◽  
V. Damyanova ◽  
A. Yavorova ◽  
A. Radinov

AbstractGaucher disease (GD) is a multi-systemic disease with a low population frequency. It is a lysosomal storage disorder (LSD) that causes accumulation of glucocerebroside in the so called Gaucher cells predominantly in areas like the spleen, liver and bone marrow. Type I GD (GDI) is the most common form and usually does not involve the brain and the spinal cord. The symptoms can range from mild to severe and may appear anytime from childhood to adulthood. Diagnostics can often be challenging and imposes looking at person’s medical history, symptoms, physical exam, and laboratory test results. We present a difficult to diagnose case of a 34-year-old woman admitted to the Clinic of Hematology, “Sv. I. Rilski” hospital with splenomegaly, normal laboratory findings and non-enlarged liver. She didn’t show focal neurological symptoms. A series of tests were assigned including genetic targeted analysis. The case is an example of a rare genetic disease with mild clinical symptoms. Diagnosis of Gaucher disease, type I was confirmed by measurement of a GBA enzyme activity and identification of mutations in the GBA gene inherited in an autosomal recessive manner. Thanks to the efforts of the clinical team, the assignment of adequate clinical and laboratory tests and their correct interpretation, the patient was subjected to enzyme replacement therapy (ERT). Although the diagnosis was settled relatively late (at 34 years of age), the correct therapy slowed down the invalidation and improved the quality of life of the patient.


Sign in / Sign up

Export Citation Format

Share Document